Competitive Technologies: Short Squeeze Coming or Another Leg Down?

David Greene submits:Competitive Technologies (CTT) has advanced from $1.50 a mere ten days ago to $3.00 today as the company announced the future publication of a renowned cancer center clinical study on the efficacy of CTT's pain management technology and in reaction to a very positive shareholders' meeting on Monday, April 19.

David Greene submits:Competitive Technologies (CTT) made a new 52-week high at $3.57 yesterday (May 13) on 5X average daily trading volume before doing an understandable retracement, which is continuing today at $2.90.

David Greene submits:Competitive Technologies (NYSE Amex: CTT), a company with a groundbreaking chronic pain therapy system utilizing electrical impulses instead of narcotic painkillers, has been a disappointment to shareholders over the past year--until a few days ago.

MONTREAL – The Caisse de dépôt et placement du Québec has plowed $8.3-billion on new investments in its home province since 2009, part of its strategy to bet money on assets it knows best while stoking economic growth. Now its real estate arm is getting into the nation-building game.

Nicholas Marshi submits:Solar Capital (SLRC) announced yesterday a private placement of equity at a price of $22.94, intended to raise $44mn in new equity. Solar Capital is a newly minted, mid-sized Business Development Company (or "BDC").

David Greene submits:The largest order in Competitive Technologies' (CTTC.PK) history for the proprietary Calmare Pain Therapy Management device was announced Tuesday (Oct. 5). The record order was from Spero Pain Relief Therapy, LLC. to equip 13 new clinics which will open over the next two years in Utah, Nevada and Southern California.

By Brian Marckx: $22M Financing ($19M New) On 1/6/12 Transgenomic Inc. (TBIO) filed an 8-K announcing a $3 million commitment by Third Security to purchase convertible promissory notes. Terms of the notes included an annual interest rate of 16%, maturity of 3/31/12 and automatic conversion into common stock upon the future sale of equity of at least $3 million. Conversion price determined by the price per share paid by buyers of the (future) equity issuance.

David Greene submits:Competitive Technologies (CTTC.PK) has had a difficult twelve months, including a change in management. However, the turnaround appears to be at hand. The company's proprietary technology for the treatment of chronic pain, known as Calmare(R) or MC‐5A , has been developing some long-awaited sales momentum with entrepreneurial physicians-- physicians who have evaluated the technology in their own offices, with their own patients.